Gyre Therapeutics
GYRE
64 hedge funds and large institutions have $118M invested in Gyre Therapeutics in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 17 closing their positions.
637% more call options, than puts
Call options by funds: $2.31M | Put options by funds: $313K
17% more capital invested
Capital invested by funds: $101M → $118M (+$16.9M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 74 → 64 (-10)
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$6.46M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$5.21M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$1.55M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$670K |
| 5 |
AIA
Arbor Investment Advisors
Winston Salem,
North Carolina
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.88M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.25M |
| 3 |
BC
Broadfin Capital
New York
|
-$1.24M |
| 4 |
Goldman Sachs
New York
|
-$1.05M |
| 5 |
Millennium Management
New York
|
-$992K |
GYRE Hedge Fund Activity: Q1 2014 in Review
64 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2014, worth a combined $118M — up 17% from $101M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of GYRE and 8 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 18 added.
The largest buyer was Camber Capital Management, adding an estimated $6.46M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.88M sold.
- 64 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2014, down from 74 in Q4 2013.
- Funds reported $118M of Gyre Therapeutics stock for Q1 2014, up 17% quarter-over-quarter.
- 8 funds opened new Gyre Therapeutics positions in Q1 2014 and 17 closed out, a net change of -9 holders.
- The largest Gyre Therapeutics buyer in Q1 2014 was Camber Capital Management, an estimated $6.46M added.
- The largest Gyre Therapeutics seller in Q1 2014 was Wellington Management Group, an estimated $3.88M sold.
Based on aggregated 13F filings for Q1 2014.